1.
              Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 1029. 
                      Find this article online
                    
2.
              Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, et al. (1997) The Heidelberg classification of renal cell tumours. J Pathol 183: 131133. 
                      Find this article online
                    
3.
              Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint , et al.. (2012) NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.1. Association of the Nordic Cancer Registries. March 2012 ed: Danish Cancer Society. 
4.
              Iliopoulos O, Kaelin WG (1997) The molecular basis of von Hippel-Lindau disease. Mol Med 3: 289293. 
                      Find this article online
                    
5.
              Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, et al. (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14: 47264734. 
                      Find this article online
                    
6.
              Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 8590.
        doi:
        10.1038/ng0594-85.
       
                      Find this article online
                    
7.
              Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 20002011. 
                      Find this article online
                    
8.
              Scharnhorst V, van der Eb AJ, Jochemsen AG (2001) WT1 proteins: functions in growth and differentiation. Gene 273: 141161. 
                      Find this article online
                    
9.
              Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, et al. (1990) An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms tumor. Cell 61: 12571269.
        doi:
        10.1016/0092-8674(90)90690-G.
       
                      Find this article online
                    
10.
              Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, et al. (2010) Wilms tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 103: 12551262.
        doi:
        10.1038/sj.bjc.6605878.
       
                      Find this article online
                    
11.
              Yang L, Han Y, Suarez Saiz F, Minden MD (2007) A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868876. 
                      Find this article online
                    
12.
              Huff V (2011) Wilms tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11: 111121. 
                      Find this article online
                    
13.
              Little M, Wells C (1997) A clinical overview of WT1 gene mutations. Hum Mutat 9: 209225. 
                      Find this article online
                    
14.
              Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, et al. (1991) Germline mutations in the Wilms tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67: 437447.
        doi:
        10.1016/0092-8674(91)90194-4.
       
                      Find this article online
                    
15.
              Barbaux S, Niaudet P, Gubler MC, Grunfeld JP, Jaubert F, et al. (1997) Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17: 467470.
        doi:
        10.1038/ng1297-467.
       
                      Find this article online
                    
16.
              Renneville A, Kaltenbach S, Clappier E, Collette S, Micol JB, et al. (2010) Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia 24: 476480.
        doi:
        10.1038/leu.2009.221.
       
                      Find this article online
                    
17.
              Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, et al. (2009) WT1 mutations in T-ALL. Blood 114: 10381045. 
                      Find this article online
                    
18.
              King-Underwood L, Renshaw J, Pritchard-Jones K (1996) Mutations in the Wilms tumor gene WT1 in leukemias. Blood 87: 21712179. 
                      Find this article online
                    
19.
              Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, et al. (2009) Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 113: 59515960. 
                      Find this article online
                    
20.
              Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, et al. (2010) WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 115: 52225231. 
                      Find this article online
                    
21.
              Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, et al. (2008) Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26: 45954602. 
                      Find this article online
                    
22.
              Virappane P, Gale R, Hills R, Kakkas I, Summers K, et al. (2008) Mutation of the Wilms tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26: 54295435. 
                      Find this article online
                    
23.
              Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, et al. (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28: 578585. 
                      Find this article online
                    
24.
              Becker H, Maharry K, Radmacher MD, Mrozek K, Metzeler KH, et al. (2011) Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica 96: 14881495. 
                      Find this article online
                    
25.
              Choi Y, Lee JH, Hur EH, Kang MJ, Kim SD, et al. (2012) Single nucleotide polymorphism of Wilms tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Ann Hematol 91: 671677.
        doi:
        10.1007/s00277-011-1355-4.
       
                      Find this article online
                    
26.
              Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, et al. (2007) Renal cell carcinoma guideline. Eur Urol 51: 15021510. 
                      Find this article online
                    
27.
              Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655663.
        doi:
        10.1097/00000478-198210000-00007.
       
                      Find this article online
                    
28.
              Greene FL, Sobin LH (2002) The TNM system: our language for cancer care. J Surg Oncol 80: 119120. 
                      Find this article online
                    
29.
              Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, et al. (2009) Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 113: 45054511.
        doi:
        10.1182/blood-2008-10-183392.
       
                      Find this article online
                    
30.
              Andersson C, Li X, Lorenz F, Golovleva I, Wahlin A, et al. (2012) Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol 21: 225233. 
                      Find this article online
                    
31.
              Royer-Pokora B, Beier M, Henzler M, Alam R, Schumacher V, et al. (2004) Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A 127A: 249257. 
                      Find this article online
                    
32.
              Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, et al. (2011) WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the childrens oncology group. J Clin Oncol 29: 704711. 
                      Find this article online
                    
33.
              Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, et al. (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 5258. 
                      Find this article online
                    
34.
              The International HapMap Consortium (2003) The International HapMap Project. Nature 426: 789796. 
                      Find this article online
                    
35.
              Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67: 96099612. 
                      Find this article online
                    
36.
              Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, et al. (2004) Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms tumours. Hum Mol Genet 13: 405415. 
                      Find this article online
                    
37.
              Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, et al. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27: 51955201.
        doi:
        10.1200/JCO.2009.22.4865.
       
                      Find this article online
                    
38.
              Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, et al. (2008) Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 93: 921924. 
                      Find this article online
                    
39.
              Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, et al. (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89: 14051412. 
                      Find this article online
                    
40.
              Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, et al. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 30713079. 
                      Find this article online
                    
41.
              Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P (2004) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 125: 590600. 
                      Find this article online
                    
42.
              Osaka M, Koami K, Sugiyama T (1997) WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. Int J Cancer 72: 696699.
        doi:
        <696::AID-IJC23&gt;3.0.CO;2-8">10.1002/(SICI)1097-0215(19970807)72:4&lt;696::AID-IJC23&gt;3.0.CO;2-8.
       
                      Find this article online
                    
43.
              Sugiyama H (2001) Wilms tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73: 177187. 
                      Find this article online
                    
44.
              Hollink IHIM, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters STCJM, et al. (2010) No Prognostic Impact of the WT1 Gene Single Nucleotide Polymorphism rs16754 in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology 28: E523E526. 
                      Find this article online
                    
45.
              Chen X, Yang Y, Huang Y, Tan J, Chen Y, et al.. (2012) WT1 mutations and single nucleotide polymorphism rs16754 analysis of patients with pediatric acute myeloid leukemia in a Chinese population. Leuk Lymphoma. 
46.
              Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A silent polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525528. 
                      Find this article online
                    
47.
              Nakamura Y, Gojobori T, Ikemura T (2000) Codon usage tabulated from the international DNA sequence databases: status for the year 2000. Nucl Acids Res: Oxford Journals. 292. 
48.
              Komar AA, Lesnik T, Reiss C (1999) Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation. FEBS Lett 462: 387391. 
                      Find this article online
                    
49.
              Kageyama Y, Yamamura Y, Oshima H, Ikawa Y (1995) Infrequent mutations of the WT1 gene in primary cancers of the adult urinary tract. Jpn J Clin Oncol 25: 173178. 
                      Find this article online
                    